Gilead Sciences, Inc. Q2 FY26 Earnings Analysis

- HIV sales expected to grow 8% year-over-year in 2026, up from prior 6% growth guidance. - Yeztugo sales forecasted at approximately $1 billion in 2026, increased from $800 million earlier. - Total 2026 product sales anticipated between $30 billion and $30.4 billion, a $400 million increase. - Base business growth projected at 5%-6% for 2026, reflecting strong commercial momentum. - Antito-cel launch revenue expected to begin in early 2027, targeting a $3.5 billion fourth-line-plus CAR-T market. - Up to 4 additional product launches planned before end of 2026. - Five Phase III trial updates anticipated in 2026, supporting pipeline growth. - Steady market expansion in HIV prevention with Yeztugo's increased uptake in both naive and switch patient segments. - Continued commercial outperformance and disciplined expense management expected to sustain margin strength.

- Gilead expects full-year 2026 operating income of $2.4 billion to $2.9 billion, factoring in acquisitions and related expenses. - Excluding upfront payments from acquisitions, operating income is projected between $14 billion and $14.5 billion, an increase of $200 million from prior guidance. - Full-year 2026 non-GAAP loss per share is guided between $1.05 and $0.65 due to acquisition costs; excluding these, non-GAAP diluted EPS is $8.45 to $8.85, consistent with earlier guidance. - The company anticipates manageable incremental expenses in 2026 and 2027 due to acquisitions with room for margin expansion beyond 2027, supported by portfolio growth. - Expect continued strong financial performance with potential to strengthen margins over time, despite quarter-to-quarter variability. - Near-term business development focuses on integration and clinical momentum, with limited large M&A expected in 2026.

- Gilead has made multiple recent strategic acquisitions: Arcellx (closed), Ouro Medicines and Tubulis (expected to close soon), adding best-in-class CAR-Ts, T cell engagers, antibody-drug conjugates, and novel technologies. - They plan to invest in clinical programs related to these acquisitions, driving a mid-single-digit percentage increase in R&D expenses for 2026. - Upfront IPR&D investments of approximately $11.8 billion are planned for 2026, including upfront payments associated with these acquisitions. - The company will focus on closing and integrating these acquisitions, maintaining strong clinical momentum. - While large M&A deals are less likely in 2026, Gilead remains open to strategic acquisitions if compelling opportunities arise. - Continued investments in product launches and pipeline development, including cell therapy (anito-cel), once-yearly HIV prevention (Yeztugo), and ADC platform expansion through Tubulis technology. - Emphasis on disciplined financial management to absorb acquisition-related expenses while maintaining margin expansion.

- The company expects incremental financing expenses in 2026 related to recent acquisitions (Arcellx, Ouro Medicines, Tubulis), contributing to about $400 million in incremental expenses, with a portion being financing expenses. - Despite these expenses, the company is effectively offsetting the impact with revenue outperformance and disciplined expense management. - They mention transaction financing expenses amounting to approximately $9.50 per share reflected in the EPS guidance for 2026. - There is no explicit mention of plans for new fundraising through additional debt or equity in the immediate future. - The management indicated it is less likely that they will pursue sizable M&A this year but remain open to strategic acquisitions if compelling opportunities arise. - Current financial strategy emphasizes disciplined financial management and operational expense prioritization without signaling imminent fundraising events.

The provided document does not explicitly mention current or expected orderbook or pending orders figures. However, relevant commercial performance and outlook details include: - Strong first-quarter sales of $6.9 billion, up 5% year-over-year. - HIV commercial sales of $5 billion, up 10% year-over-year. - Yeztugo showing strong launch performance with updated $1 billion revenue guidance for 2026. - BIC/LEN anticipated launch in late August 2026 with modest revenues in 2026 and ramp in 2027. - Trodelvy showing 37% year-on-year growth. - Pipeline and acquisition-related products progressing with expected launches and approvals in 2026-2027. - Updated 2026 revenue guidance increased by $400 million reflecting 1Q outperformance and momentum. No direct data on orderbook or pending orders is disclosed in the excerpts provided.